TP53 and cancer: Considerable attention has been given to investigating the utilization of the miRNA-34a (miR-34a) as a target of ncRNA “vaccines”, because it is considered a tumor suppressor that acts in synergy with p53 and may be downregulated in several malignant neoplasms from diverse origins, including prostate, bladder, lung, breast, gastrointestinal, pancreas, liver, head and neck, ovary, bone and hematopoietic [45,46].